|Title:||Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology|
|Authors:||Ragulina, V. A.|
Kostina, D. A.
Dovgan, A. P.
Burda, Y. E.
Nadezhdin, S. V.
nuclear factor kappa B
|Citation:||Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology / V. A. Ragulina [и др.] // Research result. Pharmacology and clinical pharmacology. - 2017. - Vol.3, №1.-P. 114-124. - DOI : 10.18413/2500-235X-2017-3-1-114-124. - Refer.: p. 120-124.|
|Abstract:||The nuclear factor kappa B (NF-κB) is one of transcription factors. A high interest in studying the biological role of the signal system and its contribution to the development of cardiovascular, oncological and autoimmune diseases is obvious. A number of stimuli (proinflammatory cytokines: tumor necrosis factor α, interleukin 1β, ligand CD40 and others) trigger the canonical and non-canonical pathways of NF-κB signaling, which increase the expression of genes regulating synthesis of cytokines and chemokines, cell proliferation and differentiation, angiogenesis, immune reactions and apoptosis. However, pathological activation of NF-κB violates the balance of substances participating in the normal activity of the cardiovascular system. This leads to the development and progression of endothelium-associated pathology and comorbidity|
|Appears in Collections:||Research Result. Pharmacology and Clinical Pharmacology|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.